ACRS
Aclaris Therapeutics, Inc.
stockNASDAQ
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.90 | 2026-11-06 | +0.26% | 5.134 |
| 1M | 3.47 | 2026-10-13 | +12.68% | 1.587 |
| 3M | 5.86 | 2026-08-13 | -33.28% | 0.852 |
| 6M | 5.09 | 2026-05-13 | -23.18% | 1.266 |
| 1Y | 2.32 | 2025-11-13 | +68.53% | 0.684 |
| 2Y | 2.44 | 2024-11-13 | +60.25% | — |
| 5Y | 14.91 | 2021-11-12 | -73.78% | 0.986 |
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) stock price today is $3.91, and today's volume is 1,014,169. ACRS is down 2.250% today. The 30 day average volume is 3.42M. ACRS market cap is $620.17M with 158.61M shares outstanding.